About BioDtech
BioDtech is a Healthcare company based in Birmingham (United States) founded in 2003, and was acquired by Predictive Oncology in July 2020. Endotoxin detection, neutralization, and removal technologies are developed. BioDtech has raised $1.6 million across 3 funding rounds from investors including Predictive Oncology, HHS and Greer Capital Advisors. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Reagents and Kits and Diversified. Its competitors include GenScript, Teknova and Meridian Bioscience; 1 of its 3 listed competitors has raised funding.
Company details
BioDtech was founded in 2003 and is based in Birmingham, United States. Products for the bioresearch and bioprocess sectors are developed, focusing on endotoxin detection, neutralization, and removal. Reagents for assay development are provided, along with services for endotoxin detection and removal from aqueous solutions using EndoBind-R technology. A license agreement with the National University of Singapore grants worldwide rights for these products.
- Headquarters Birmingham, United States
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website biodtechinc.com
- Social LinkedIn
- Acquired by Predictive Oncology (Jul 2020)
- Total Equity Funding$1.6M (USD)
in 3 rounds
- Latest Funding Round$1.13M (USD), Grant
Sep 2014
- InvestorsPredictive Oncology
& 2 more
- Acquired byPredictive Oncology
(Jul 2020)
Funding Insights of BioDtech
BioDtech has successfully raised a total of $1.6M across 3 strategic funding rounds. The most recent funding activity was a Grant round of $1.13 million completed in September 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $1.6M
- Total Rounds 3
- Last Round Grant — $1.13M
- First Round $1M
(Jul 2007)
- Investors Count 2
All 3 funding rounds of BioDtech with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2014 | $1.13M | Grant | – | – | |
| Aug 2010 | $600,000 | Seed | – | Greer Capital Advisors | – |
| Jul 2007 | $1M | Seed | – | Greer Capital Advisors | – |
3 investors in total: 3 institutional.
Investors in BioDtech
BioDtech has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include Predictive Oncology, HHS and Greer Capital Advisors.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| greercap.com | ||||
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
AI-based platform for cancer diagnostics and precision medicine is utilized. | 2002 | predictive-oncology.com | Eagan, United States |
Investor details for BioDtech
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of BioDtech
4 dated milestones of BioDtech across 17 years, from founding to its latest funding, stage changes and deals.
- Founded BioDtech is founded.
- Funding First funding round of $1.0M.
- Funding Latest funding round, Grant, of $1.1M.
- Exit Acquired by Predictive Oncology.
Competitors of BioDtech
BioDtech has 3 listed competitors in our database, 1 of them funded. They include GenScript, Teknova and Meridian Bioscience.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| genscript.com | 2002 | Piscataway, United States | $15M | 5,260 | Reagents and instruments are provided for life sciences research. | |
| teknova.com | 1996 | Hollister, United States | 290 | Molecular biology reagents and kits are supplied for research applications. | ||
| meridianbioscience.com | 1976 | Ohio, United States | Molecular diagnostic device and kits |
Detailed competitors of BioDtech
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as BioDtech (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Biodtech
Complete news archive for BioDtech
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about BioDtech
BioDtech was founded in 2003 and raised its 1st funding round 4 years after it was founded.
BioDtech is headquartered in Birmingham, United States. It is registered at Birmingham, Alabama, United States.
BioDtech is a funded company, having raised a total of $1.6M across 3 funding rounds to date. The company's 1st funding round was a Seed of $1M, raised on Jul 2007.
BioDtech was founded in 2003 and is based in Birmingham, United States. Products for the bioresearch and bioprocess sectors are developed, focusing on endotoxin detection, neutralization, and removal. Reagents for assay development are provided, along with services for endotoxin detection and removal from aqueous solutions using EndoBind-R technology. A license agreement with the National University of Singapore grants worldwide rights for these products.
BioDtech's top competitors include Meridian Bioscience, GenScript and Teknova.
BioDtech has 3 investors. Key investors include Predictive Oncology, HHS, and Greer Capital Advisors.
Yes. BioDtech was acquired by Predictive Oncology in July 2020.